News
BiBBInstruments carries out a directed issue of shares to guarantors
THIS PRESS RELEASE MAY NOT BE DISTRIBUTED, RELEASED OR PUBLISHED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS,...
Shareholding notification in BiBBInstruments AB (publ)
BiBBInstruments AB (publ) (“BiBBInstruments” or the “Company”) hereby announces, in connection with the recently completed rights issue in the Company, that...
BiBBInstruments announces outcome in rights issue
The Board of Directors of BiBBInstruments AB (“BiBBInstruments” or the “Company”) today announces the outcome of the rights issue of shares...
BiBBInstruments receives additional subscription intentions in the ongoing rights issue
THIS PRESS RELEASE MAY NOT BE DISTRIBUTED, RELEASED OR PUBLISHED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS,...
Correction: BiBBInstruments AB (publ) publishes updated information document in connection with rights issue – incorrect ISIN code for the share
BiBBInstruments AB (publ) (“BIBB” or the “Company”) today publishes an updated information document in connection with the rights issue of shares...
BiBBInstruments AB (publ) publishes information document in connection with rights issue
BiBBInstruments AB (publ) (“BIBB” or the “Company”) today publishes an information document in connection with the rights issue of shares resolved...
BiBBInstruments resolves on the previously announced rights issue of approximately SEK 60.3 million
THIS PRESS RELEASE MAY NOT BE DISTRIBUTED, RELEASED OR PUBLISHED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS,...
Communiqué from the Extraordinary General Meeting in BiBBInstruments AB held on 13 March 2026
Today, March 13, 2026, an extraordinary general meeting was held in BiBBInstruments AB (publ) (“BiBB” or “the Company”). Below is a...
Notice of Extraordinary General Meeting of BiBBInstruments AB (publ)
The shareholders of BibbInstruments AB (publ), 556938-9512, are hereby invited to attend an extraordinary general meeting on Friday, March 13 2026,...
BiBBInstruments Announces the Board of Directors’ Intention to Resolve on a Rights Issue of Approximately SEK 60 Million
THIS PRESS RELEASE MAY NOT BE DISTRIBUTED, RELEASED OR PUBLISHED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS,...
BiBBInstruments receives additional orders for EndoDrill® GI from the U.S.
The cancer diagnostics company BiBBInstruments AB (“BiBB” or the “Company”) announces that additional orders have so far been received from the...
EndoDrill® GI has officially launched in the United States.
BiBBInstruments AB (“BiBB” or the “Company”), a Swedish cancer diagnostics company, announces the official launch of EndoDrill® GI in the United...
Initial Results from Mayo Clinic Indicate Potential of EndoDrill® GI in Tissue Culture-Based Pancreatic Cancer Research
BiBBInstruments AB (“BiBB” or the “Company”), a cancer diagnostics company, today announces that a research team from Mayo Clinic in Jacksonville...
BiBB Engages EUS Pioneer Professor Peter Vilmann as Scientific Advisor
BiBBInstruments AB (“BiBB” or the “Company”), a cancer diagnostics company, today announces that Professor Peter Vilmann, a world-renowned pioneer who performed...
Henry Ford St. John Hospital Reports First U.S. Liver Biopsy Cases with EndoDrill® GI
The cancer diagnostics company BiBBInstruments AB (“BiBB” or the “Company”) today announces that Henry Ford St. John Hospital & Medical Center...
Decision to Grant Third EndoDrill® Patent in Japan
Cancer diagnostics company BiBBInstruments AB (“BiBB” or the “Company”), developer of EndoDrill® – the world’s first market-cleared powered biopsy instrument for...
BiBBInstruments announces date for conversion of exercised warrants of series TO 1 into shares
BiBBInstruments AB (“BiBB” or the “Company”) announces that the Swedish Companies Registration Office has registered the shares subscribed for through the...
BiBB signs exclusive distribution agreement with TaeWoong Medical USA
BiBBInstruments AB (“BiBB” or the “Company”), developer of EndoDrill® – the world’s first market-cleared powered biopsy instrument for endoscopy – announces...
BiBBInstruments AB announces outcome of subscription period for warrants of series TO 1
BiBBInstruments AB (”BiBB” or the ”Company”) today announces the outcome of the subscription period för warrants of series TO 1 (the...
BiBBInstruments AB – Receives intention of subscription regarding warrants of series TO 1 from management and board members
BiBBInstruments AB (“BiBB” or the “Company”) announces today that the Company has received intention of subscription from six members of its...
BiBBInstruments AB: Publishes a letter from CEO Fredrik Lindblad
BiBBInstruments AB (“BiBB” or the “Company”) publishes a letter from the CEO, Fredrik Lindblad, due to the beginning of the subscription...
BiBBInstruments AB – The subscription period for warrants of series TO 1 begins today
The subscription period for the warrants of series TO 1 (“Warrants” or “TO 1”) that BiBBInstruments AB (“BiBB” or the “Company”)...
BiBBInstruments AB: The subscription price for warrants of series TO 1 set at SEK 3.25 per share
BiBBInstruments AB (“BiBB” or the “Company”) issued a total of 2,755,282 warrants of series TO 1 (“the Warrants” or “TO1”) in...
BiBB Receives U.S. Patent Notice of Allowance for EndoDrill®
BiBBInstruments AB (“BiBB” or the “Company”), a cancer diagnostics company developing EndoDrill® – the world’s first market-cleared powered biopsy instrument for...
BiBB Receives Notice of Allowance for Additional EndoDrill Patent in China
The cancer diagnostics company BiBB Instruments AB (“BiBB” or “the Company”), which develops EndoDrill® – the world’s first market-cleared powered biopsy...
Successful Live Broadcasted Patient Case with EndoDrill® GI in Porto, Portugal
The cancer diagnostics company BiBBInstruments AB (“BiBB” or “the Company”), which develops EndoDrill® – the world’s first CE-marked electric-driven biopsy instrument...
First liver cases with EndoDrill GI performed in the USA
The cancer diagnostics company BiBBInstruments AB (“BiBB” or the “Company”), the developer of EndoDrill® – the world’s first market-cleared powered biopsy...
BiBB participated in clinical cases with EndoDrill GI in Germany for the indication EUS-guided liver biopsy
The cancer diagnostics company BiBBInstruments AB (“BiBB or the “Company”), the developer of EndoDrill®, the world’s first market-cleared, powered biopsy instrument...
BiBB receives first order for EndoDrill GI from a university hospital in the US
The cancer diagnostics company BiBBInstruments AB (“BiBB or the “Company”), the developer of EndoDrill®, the world’s first market-cleared, electric-driven biopsy instrument...
BiBBInstruments announces final outcome of rights issue
BiBBInstruments AB (“BiBB” or the “Company”) today announces the final outcome of the rights issue of units of approximately SEK 36.5...
BiBBInstruments announces preliminary outcome of rights issue
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG...
Clinical evaluation at Karolinska University Hospital is progressing
The cancer diagnostics company BiBBInstruments AB (“BiBB or the “Company”), the developer of EndoDrill®, the world’s first market-cleared, electric-driven biopsy instrument...
Well-executed clinical introduction of EndoDrill® GI at Sahlgrenska University Hospital in Sweden
The cancer diagnostics company BiBBInstruments AB (“BiBB” and the “Company”), the developer of EndoDrill®, the world’s first market-cleared electric-driven biopsy instrument...
BiBB has initiated a collaboration with Swedish contract manufacturer Cenova
The cancer diagnostics company BiBBInstruments AB (“BiBB” and the “Company”), the developer of EndoDrill®, the world’s first market-cleared electric-driven biopsy instrument...
Impressive US Clinical Case Series presented at ACG 2024 in Philadelphia
The cancer diagnostics company BiBBInstruments AB (“BiBB or the “Company”), the developer of the world’s first market-cleared electric-driven biopsy instrument for...
BiBB receives an Intention to Grant for EndoDrill patent in China
The cancer diagnostics company BiBBInstruments AB (“BiBB”), the developer of the world’s first market-cleared electric-driven biopsy instrument for endoscopy, today announces...
New Peer-Reviewed Clinical Case Series in the U.S. Shows 100% Diagnostic Accuracy with EndoDrill GI
The cancer diagnostics company BiBBInstruments AB (“BiBB or the “Company”), the developer of the world’s first market-cleared electric-driven biopsy instrument for...
EndoDrill GI sparks interest at the 7th Nordic EUS Meeting in Copenhagen
The cancer diagnostics company BiBBInstruments AB (“BiBB or the “Company”), the developer of the world’s first market-cleared electric-driven biopsy instrument for...
BiBB receives an Intention to Grant for EndoDrill patent in Europe
The cancer diagnostics company BiBBInstruments AB (“BiBB”), the developer of the world’s first market-cleared electric-driven biopsy instrument for endoscopy, today announces...
Successful introduction of EndoDrill GI at University Hospital Center Sestre Milosrdnice in Zagreb, Croatia
The cancer diagnostics company BiBBInstruments AB (“BiBB”), the developer of the world’s first market-cleared electric-driven biopsy instrument for endoscopy, announces that...
EndoDrill is recognized as a promising new product for solving a significant clinical problem in a medical journal
The cancer diagnostics company BiBBInstruments AB (“BiBB”), the developer of EndoDrill®, the world’s first market-cleared motorized endoscopic core biopsy instrument, informs...
BiBBInstruments AB carries out a directed share issue of SEK 10.0 million
The Board of Directors of the cancer diagnostics company BiBBInstruments AB (publ) (“BiBB” or the “Company”) has, based on the authorization...
Successful case studies with EndoDrill GI continue in Norway and Sweden
The cancer diagnostics company BiBBInstruments AB (“BiBB” or the “Company”), the developer of the world’s first market-cleared electric-driven biopsy instrument for...
EndoDrill presented as New Kid on the Block at ESGE Days
The cancer diagnostics company BiBBInstruments AB (“BiBB” or the “Company”), the developer of the world’s first market-cleared electric-driven biopsy instrument for...
Successful clinical pilot study with EndoDrill GI published in peer reviewed scientific journal
The cancer diagnostics company BiBBInstruments AB (“BiBB” or the “Company”), the developer of the world’s first market-cleared electric-driven biopsy instrument for...
First clinical cases with EndoDrill® GI successfully performed at Karolinska University Hospital in Sweden
The cancer diagnostics company BiBBInstruments AB (“BiBB” or the “Company”), the developer of the world’s first market-cleared electric-driven biopsy instrument for...
Japanese Patent Office Issues Decision to Grant Patent for EndoDrill Technology
The cancer diagnostics company BiBBInstruments AB (“BiBB” or the “Company”), the developer of the world’s first market-cleared electric-driven endoscopic core biopsy...
UC Davis Health reports positive clinical experiences with EndoDrill GI
The cancer diagnostics company BiBBInstruments AB (“BiBB” or the “Company”), the developer of the world’s first market-cleared electric-driven endoscopic core biopsy...
BiBB launches new website
The cancer diagnostics company BiBBInstruments AB (“BiBB” or the “Company”), the developer of the world’s first market-cleared motorized endoscopic core biopsy...
BiBB Receives European CE Mark Approval According to MDR for the Entire EndoDrill Product Family
The cancer diagnostics company BiBBInstruments AB (“BiBB” or the “Company”), which has developed the world’s first electric-driven endoscopic biopsy instrument, announces...
First US clinical cases successfully conducted with EndoDrill GI
The cancer diagnostics company BiBBInstruments AB (“BiBB” or the “Company”), the developer of the world’s first market-cleared motorized endoscopic core biopsy...
BiBB receives approval of two patents in Europe for EndoDrill
The cancer diagnostics company BiBBInstruments AB (“BiBB or the “Company”) today announces that the European Patent Office (EPO) has finally approved...
BiBB reports positive results from clinical pilot study with EndoDrill URO
The cancer diagnostics company BiBBInstruments AB (“BiBB” or the “Company”) today reports that the first clinical study with EndoDrill® URO for...
BIBB informs about the status of the CE marking process according to MDR
The cancer diagnostics company BiBBInstruments AB (“BiBB” or the “Company”), which develops and manufactures a new type of electric-driven endoscopic biopsy...
BIBB receives market clearance for EndoDrill GI in the US
The cancer diagnostics company BiBBInstruments AB (“BiBB” or the “Company”), which develops and manufactures a new type of electric-driven endoscopic biopsy...
BiBB receives another Intention to Grant notice for EndoDrill in Europe
Today, the cancer diagnostics company BiBBInstruments AB (“BiBB” or the “Company”) announces that the Company has received an additional Intention to...
BiBB receives an Intention to Grant for electric-driven EndoDrill in Europe
The cancer diagnostics company BiBBInstruments AB (“BiBB or the “Company”) announces that the Company has received an Intention to Grant from...